These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 34455083)

  • 21. Validation of N Protein Antibodies to Diagnose Previous SARS-CoV-2 Infection in a Large Cohort of Healthcare Workers: Use of Roche Elecsys
    Delgado JF; Vidal M; Julià G; Navarro G; Serrano RM; van den Eynde E; Navarro M; Calvet J; Gratacós J; Espasa M; Peña P
    Viruses; 2023 Apr; 15(4):. PubMed ID: 37112910
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preliminary evidence of blunted humoral response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients treated with ocrelizumab.
    Gallo A; Capuano R; Donnarumma G; Bisecco A; Grimaldi E; Conte M; d'Ambrosio A; Coppola N; Galdiero M; Tedeschi G
    Neurol Sci; 2021 Sep; 42(9):3523-3526. PubMed ID: 34128150
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of BNT162b2 primary vaccination and homologous booster on anti-SARS-CoV-2 IgA antibodies in baseline seronegative healthcare workers.
    Salvagno GL; Henry BM; Pighi L; De Nitto S; Lippi G
    Adv Lab Med; 2022 Jun; 3(2):167-174. PubMed ID: 37361867
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis.
    Schrezenmeier E; Bergfeld L; Hillus D; Lippert JD; Weber U; Tober-Lau P; Landgraf I; Schwarz T; Kappert K; Stefanski AL; Sattler A; Kotsch K; Dörner T; Sander LE; Budde K; Halleck F; Kurth F; Corman VM; Choi M
    Front Immunol; 2021; 12():690698. PubMed ID: 34276681
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2.
    Havervall S; Marking U; Greilert-Norin N; Ng H; Gordon M; Salomonsson AC; Hellström C; Pin E; Blom K; Mangsbo S; Phillipson M; Klingström J; Hober S; Nilsson P; Åberg M; Thålin C
    EBioMedicine; 2021 Aug; 70():103523. PubMed ID: 34391088
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Performance evaluation of the Roche Elecsys Anti-SARS-CoV-2 S immunoassay.
    Riester E; Findeisen P; Hegel JK; Kabesch M; Ambrosch A; Rank CM; Pessl F; Laengin T; Niederhauser C
    J Virol Methods; 2021 Nov; 297():114271. PubMed ID: 34461153
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Short-term antibody response after 1 dose of BNT162b2 vaccine in patients receiving hemodialysis.
    Goupil R; Benlarbi M; Beaubien-Souligny W; Nadeau-Fredette AC; Chatterjee D; Goyette G; Gunaratnam L; Lamarche C; Tom A; Finzi A; Suri RS;
    CMAJ; 2021 May; 193(22):E793-E800. PubMed ID: 33980499
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Decline of antibody titres 3 months after two doses of BNT162b2 in non-immunocompromised adults.
    Erice A; Varillas-Delgado D; Caballero C
    Clin Microbiol Infect; 2022 Jan; 28(1):139.e1-139.e4. PubMed ID: 34508885
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A performance comparison of two (electro) chemiluminescence immunoassays for detection and quantitation of serum anti-spike antibodies according to SARS-CoV-2 vaccination and infections status.
    Camacho J; Albert E; Zulaica J; Álvarez-Rodríguez B; Rusu L; Olea B; Alcaraz MJ; Geller R; Giménez E; Navarro D
    J Med Virol; 2023 Jan; 95(1):e28397. PubMed ID: 36504019
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibody titers against the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2 induced by BNT162b2 vaccination measured using automated chemiluminescent enzyme immunoassay.
    Kato H; Miyakawa K; Ohtake N; Go H; Yamaoka Y; Yajima S; Shimada T; Goto A; Nakajima H; Ryo A
    J Infect Chemother; 2022 Feb; 28(2):273-278. PubMed ID: 34857462
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients.
    Trougakos IP; Terpos E; Zirou C; Sklirou AD; Apostolakou F; Gumeni S; Charitaki I; Papanagnou ED; Bagratuni T; Liacos CI; Scorilas A; Korompoki E; Papassotiriou I; Kastritis E; Dimopoulos MA
    BMC Med; 2021 Aug; 19(1):208. PubMed ID: 34420521
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of Two Chemiluminescent and Three ELISA Immunoassays for the Detection of SARS-CoV-2 IgG Antibodies: Implications for Disease Diagnosis and Patients' Management.
    Speletas M; Kyritsi MA; Vontas A; Theodoridou A; Chrysanthidis T; Hatzianastasiou S; Petinaki E; Hadjichristodoulou C
    Front Immunol; 2020; 11():609242. PubMed ID: 33424863
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improvements and limits of anti SARS-CoV-2 antibodies assays by WHO (NIBSC 20/136) standardization.
    Giavarina D; Carta M
    Diagnosis (Berl); 2021 Dec; 9(2):274-279. PubMed ID: 34851563
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dynamics of Antibody Response to BNT162b2 mRNA COVID-19 Vaccine: A 7-Month Follow-Up Study.
    Olariu TR; Ursoniu S; Marincu I; Lupu MA
    Medicina (Kaunas); 2021 Dec; 57(12):. PubMed ID: 34946275
    [No Abstract]   [Full Text] [Related]  

  • 35. Evaluation of Anti-SARS-Cov-2 S-RBD IgG Antibodies after COVID-19 mRNA BNT162b2 Vaccine.
    Lo Sasso B; Giglio RV; Vidali M; Scazzone C; Bivona G; Gambino CM; Ciaccio AM; Agnello L; Ciaccio M
    Diagnostics (Basel); 2021 Jun; 11(7):. PubMed ID: 34206567
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-spike S1 IgA, anti-spike trimeric IgG, and anti-spike RBD IgG response after BNT162b2 COVID-19 mRNA vaccination in healthcare workers.
    Salvagno GL; Henry BM; di Piazza G; Pighi L; de Nitto S; Bragantini D; Gianfilippi GL; Lippi G
    J Med Biochem; 2021 Sep; 40(4):327-334. PubMed ID: 34616222
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity.
    Mrak D; Tobudic S; Koblischke M; Graninger M; Radner H; Sieghart D; Hofer P; Perkmann T; Haslacher H; Thalhammer R; Winkler S; Blüml S; Stiasny K; Aberle JH; Smolen JS; Heinz LX; Aletaha D; Bonelli M
    Ann Rheum Dis; 2021 Oct; 80(10):1345-1350. PubMed ID: 34285048
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibodies against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) in individuals with and without COVID-19 vaccination: A method comparison of two different commercially available serological assays from the same manufacturer.
    Mueller T
    Clin Chim Acta; 2021 Jul; 518():9-16. PubMed ID: 33741357
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Kinetics of Anti-SARS-CoV-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers.
    Terpos E; Trougakos IP; Karalis V; Ntanasis-Stathopoulos I; Gumeni S; Apostolakou F; Sklirou AD; Gavriatopoulou M; Skourti S; Kastritis E; Korompoki E; Papassotiriou I; Dimopoulos MA
    Cells; 2021 Jul; 10(8):. PubMed ID: 34440710
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SARS-CoV-2 neutralizing antibodies after one or two doses of Comirnaty (BNT162b2, BioNTech/Pfizer): Kinetics and comparison with chemiluminescent assays.
    Padoan A; Cosma C; Bonfante F; Rocca FD; Barbaro F; Santarossa C; Dall'Olmo L; Pagliari M; Bortolami A; Cattelan A; Cianci V; Basso D; Plebani M
    Clin Chim Acta; 2021 Dec; 523():446-453. PubMed ID: 34755646
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.